/

Sociétés

Al

Non vérifié

Almirall

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéScience

10 communiqués de presse

Voir tous les communiqués de presse

13/04/2026

Marché du travail

Industrie

Science

Technique

Associations/Professionnels

Biotechnologie

Santé

Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology

Source

Émetteur

1.00

0

23/03/2026

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Psychiatrie

Santé Publique

Événements

Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology

Source

Émetteur

1.00

0

16/03/2026

Science

Jeunesse

Enfance

Médecine - Divers

Famille

Biotechnologie

Industrie pharmaceutique

Vitrines/Shopping

Santé

Industrie

Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis

Source

Émetteur

1.00

0

21/03/2025

Événements

Science

Biotechnologie

Industrie pharmaceutique

Santé Publique

Oncologie

Santé

Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology

Source

Émetteur

1.00

0

14/01/2025

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Source

Émetteur

1.00

0

04/12/2024

Multimédia

Industrie

Santé Publique

Science

Associations/Professionnels

Psychiatrie

Biotechnologie

Santé

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Source

Émetteur

1.00

0

25/09/2024

Multimédia

Industrie

Événements

Biotechnologie

Industrie pharmaceutique

Finance

Santé Publique

Santé

Associations/Professionnels

Médecine - Divers

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Source

Émetteur

1.00

0

23/09/2024

Industrie

Événements

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Médecine - Divers

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Source

Émetteur

1.00

0

02/07/2024

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

Source

Émetteur

1.00

0

28/06/2024

Expos

Industrie

Psychiatrie

Science

Médecine - Divers

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0